WaveBreak is a biopharmaceutical company focused on transforming drug discovery for neurodegenerative diseases, targeting the fleeting protein intermediates central to many disease pathways that are beyond the reach of conventional drug discovery approaches. WaveBreak has built a unique drug discovery platform to target the transient protein intermediates—the oligomers—in these disease pathways, to interrupt the molecular mechanisms that are the source of oligomer generation with small-molecule therapeutics. WaveBreak is focusing this platform first on some of the greatest unmet medical needs of our time: Parkinson’s disease, Lewy body dementia, Alzheimer’s disease, and ALS.

Biotechnology

Life Sciences

Pharmaceutical

WaveBreak

Bart Henderson

Dawn Adams

Joe Wilson

David Witter

Bochong Li

The Leadership Team at WaveBreak is responsible for setting the strategic direction and vision of the company, ensuring alignment and progress towards transforming drug discovery for neurodegenerative diseases. They steer major initiatives, drive innovation, manage high-level research and development, and foster partnerships to advance the company's drug discovery platform. With a focus on targeting transient protein intermediates, the team aims to develop breakthrough small-molecule therapeutics for conditions like Parkinson’s disease, Lewy body dementia, Alzheimer’s disease, and ALS.

Leadership Team

Scientific Research Team

Leadership Team

About

Team members

Other teams at WaveBreak

Scientific Research Team